NEDA TAHAMI: Open Payments
NPI 1396370326 · SAN JUAN CAPISTRANO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$622 in 30 payments from 8 companies in 2025. Trend: 2023 $645 · 2024 $631 · 2025 $622
Food & beverage: $622
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $290 |
| Otsuka America Pharmaceutical, Inc. | 5 | $121 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $73 |
| Braeburn Inc. | 2 | $50 |
| Vanda Pharmaceuticals Inc. | 1 | $30 |
| Gilead Sciences, Inc. | 1 | $26 |
| PFIZER INC. | 1 | $19 |
| AstraZeneca Pharmaceuticals LP | 1 | $14 |
Products named: VRAYLAR, REXULTI, CAPLYTA, BRIXADI, FANAPT, PREVNAR 20, AIRSUPRA.
Industry payments across CA — which companies pay providers there.
